Table 1 FRS2 immunostaining in 182 ALT/WDL/DDLs and 64 control cases
Tumor type | FRS2 immunostaining | Total | |||
|---|---|---|---|---|---|
- (%) | 1+ (%) | 2+ (%) | 3+ (%) | ||
ALT/WDL/DDL | 11 (6.0%) | 51 (28.0%) | 63 (34.7%) | 57 (31.3%) | 182 |
 ALT/WDL | 8 (8.8%) | 33 (36.3%) | 31 (34.1%) | 19 (20.8%) | 91 |
 DDL | 3 (3.3%) | 18 (19.8%) | 32 (35.2%) | 38 (41.7%) | 91 |
Control group | 47 (73.5%) | 15 (23.4%) | 2 (3.1%) | 0 (0%) | 64 |
Normal adipose tissue | 3 (100%) | 0 (0%) | 0 (0%) | 0 (0%) | 3 |
Benign adipose tumor | |||||
 Lipoma | 20 (80.0%) | 5 (20%) | 0 (0%) | 0 (0%) | 25 |
 Spindle cell lipoma | 5 (71.4%) | 2 (28.6%) | 0 (0%) | 0 (0%) | 7 |
Other spindle cell tumors | |||||
 Pleomorphic liposarcoma | 5 (62.5%) | 2 (25.0%) | 1 (12.5%) | 0 (0%) | 8 |
 Myxoid liposarcoma | 1 (50.0%) | 1 (50.0%) | 0 (0%) | 0 (0%) | 2 |
 Atypical spindle cell lipomatous tumor | 2 (66.7%) | 1 (33.3%) | 0 (0%) | 0 (0%) | 3 |
 Undifferentiated pleomorphic sarcoma | 2 (66.7%) | 1 (33.3%) | 0 (0%) | 0 (0%) | 3 |
 Myxofibrosarcoma | 5 (100%) | 0 (0%) | 0 (0%) | 0 (0%) | 5 |
 Leiomyosarcoma | 3 (60.0%) | 2 (40.0%) | 0 (0%) | 0 (0%) | 5 |
 Low-grade myofibroblastic sarcoma | 0 (0%) | 0 (0%) | 1 (100%) | 0 (0%) | 1 |
 Osteosarcoma | 0 (0%) | 1 (100%) | 0 (0%) | 0 (0%) | 1 |
 Schwannoma | 1 (100%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 |